RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay Inc. (AMEX:ISR), a medical isotope company focused on the treatment of prostate cancer and other malignant disease through use of its proprietary radioisotope technology, announced today the Board of Directors of IsoRay has authorized the repurchase of up to 1,000,000 shares of the Company’s common stock.
